Therefore, future randomized controlled clinical trials are needed to demonstrate the benefit of CS or other devices for myoglobin removal (e.g. EMiC®2) on the outcome of patients with severe rhabdomyolysis. This evidence concerns the gene MB and rhabdomyolysis.